AC Immune SA (ACIU)
| Market Cap | 425.43M |
| Revenue (ttm) | 114.46M |
| Net Income (ttm) | 46.85M |
| Shares Out | 67.56M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $5.93 |
| Previous Close | $6.12 |
| Change ($) | -0.19 |
| Change (%) | -3.10% |
| Day's Open | 6.13 |
| Day's Range | 5.87 - 6.18 |
| Day's Volume | 125,002 |
| 52-Week Range | 4.24 - 9.65 |
Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital
Prof. June is a world authority on immune tolerance and adoptive immunotherapy
Prof. Streffer is a n established authority on n euroscience and b iomarker modalities
AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat th...
LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.
Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
AC Immune S.A. (NASDAQ: ACIU) stock was absolutely crushed on Wednesday after one of the firm’s partners announced disappointing results from its midstage Alzheimer’s disease study.
Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) have lost about half their market capitalization on an adverse clinical readout for an out-licensed investigational Alzheimer's drug.
AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.
Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met
AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference
LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerat...
Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
First-in-class TDP-43 antibody developed using SurpraAntigen™ platform
AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical resul...
Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio
Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseases Presentations to highlight the Company’s broad experti...
AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.
Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company.
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study
Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool Results published in JAMA Neurology demonstrate the potential for a best-in-class diagnostic tool
LAUSANNE, Switzerland, June 26, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerati...
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Latest appointment further reinforces the depth and breadth of the Company’s clinical development competences in Down syndrome-related Alzheimer’s disease Latest appointment further reinforces...
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for January 30th
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenera...
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Lilly to pay CHF30 million development milestone
Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and neurodegenerative diseases
Company to Give an Oral Presentation at Michael J. Fox Foundation’s 13th Annual Parkinson’s Disease Therapeutics Conference Company to Give an Oral Presentation at Michael J. Fox Foundation’s ...
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-... [Read more...]
| Industry Biotechnology | IPO Date Sep 23, 2016 |
| CEO Andrea Pfeifer | Employees 115 |
| Stock Exchange NASDAQ | Ticker Symbol ACIU |
Analyst Forecasts
According to 4 analysts, the average rating for AC Immune stock is "Buy." The 12-month stock price forecast is 11.09, which is an increase of 87.02% from the latest price.